Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Background Monoclonal antibody (mAb) treatment is associated with decreased risk of
hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease …

Objectives Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against
Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought …

Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …

Background Monoclonal antibody treatment may prevent complications of coronavirus
disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Abstract Background Coronavirus disease 2019 (COVID-19) has strained healthcare
systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies …

Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild
to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the …

Abstract Study Objective Our objective was to determine if bamlanivimab (LY‐CoV555;
BAM), a monoclonal antibody for mild‐to‐moderate Severe Acute Respiratory Syndrome …